Abstract:Choosing antithrombotic therapy for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) is challenging. Oral anticoagulation is indicated to prevent stroke and systemic embolism in patients with atrial fibrillation but has not been shown to prevent stent thrombosis and is generally not indicated for secondary prevention after acute coronary syndrome. 1-3 Dual antiplatelet therapy is proven to reduce the incidence of recurrent ischemic events and stent thrombosis but is less effective in reducing the incidence of cardioembolic stroke associated with atrial fibrillation. 2-4 The combination of antithrombotic agents, particularly triple therapy with oral anticoagulation and dual antiplatelet therapy, increases the risk of bleeding. 5-7 Thus, an oral antithrombotic regimen with an acceptable benefit–risk profile would be useful in the treatment of patients with atrial fibrillation and concomitant acute coronary syndrome or PCI. Regimens including non–vitamin K antagonist oral anticoagulants appear to offer a number of advantages over vitamin K antagonists, including the potential for less bleeding. 8 Two trials evaluated standard or reduced doses of oral anticoagulants (of dabigatran and rivaroxaban, respectively) in patients with atrial fibrillation who were undergoing PCI, and both trials showed a lower incidence of bleeding with new oral anticoagulant regimens without aspirin than with vitamin K antagonist regimens that included aspirin. 9,10 Neither trial was designed to assess whether the lower incidence of bleeding was due to the use of the standard or reduced doses of the new oral anticoagulants or to the removal of aspirin therapy. We conducted the AUGUSTUS trial (a two-by-two factorial, randomized, controlled clinical trial) to assess the safety and efficacy of standard-dose apixaban as compared with a vitamin K antagonist and of low-dose aspirin as compared with placebo, on a background of concomitant P2Y 12 inhibitor therapy for 6 months in patients with atrial fibrillation and recent acute coronary syndrome or PCI. The trial was designed and led by an academic steering committee whose members were responsible for the conduct of the trial. The Duke Clinical Research Institute (DCRI, Durham, NC) was the academic coordinating center. The trial was sponsored by Bristol-Myers Squibb and Pfizer. The trial protocol (available with the full text of this article at NEJM.org) and all subsequent amendments were approved by national regulatory agencies in participating countries and by institutional review boards or ethics committees at participating sites. An independent data and safety monitoring board reviewed unblinded patient-level data at regular intervals during the trial. Although Bristol-Myers Squibb assisted with data management, all the statistical analyses were performed independently at the DCRI. The initial draft of the manuscript was written by the first author and revised on the basis of comments from the other authors. All the authors vouch for the adherence of the trial to the protocol, and the first, second, and last authors vouch for the accuracy and completeness of the data and analysis. No one who is not an author contributed to writing the manuscript. The committee members and participating investigators are listed in the Supplementary Appendix , available at NEJM.org. The trial rationale and design have been published previously. 11 In brief, AUGUSTUS was a prospective, multicenter, two-by-two factorial, randomized clinical trial comparing apixaban with a vitamin K antagonist and comparing aspirin with placebo in patients with atrial fibrillation who had a recent acute coronary syndrome or underwent PCI (or both). Patients who met all the following criteria were eligible for inclusion: an age of at least 18 years; previous, persistent, permanent, or paroxysmal atrial fibrillation and planned long-term use of an oral anticoagulant; recent acute coronary syndrome or PCI; and planned use of a P2Y 12 inhibitor for at least 6 months. Patients who were using anticoagulation for other conditions (e.g., prosthetic valves, venous thromboembolism, and mitral stenosis) were not eligible. Other key exclusion criteria were severe renal insufficiency, a history of intracranial hemorrhage, recent or planned coronary-artery bypass graft surgery, coagulopathy or ongoing bleeding, and contraindication to a vitamin K antagonist, apixaban, all P2Y 12 inhibitors, or aspirin. All the patients provided written informed consent before -Abstract Truncated-

Rivaroxaban in patients with a recent acute coronary syndrome

Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes

Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease

Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation

Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis

Results of Register in Patients with Acute Coronary Syndrome and Atrial Fibrillation Receiving Rivaroxaban.

Exploring unmet needs in venous and arterial thromboembolism with rivaroxaban

Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial

Rivaroxaban or warfarin in atrial fibrillation and coronary stent implantation in real-world patients involving chronic kidney disease (REWRAPS): 5-year follow-up study

Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial

Rivaroxaban plus aspirin after lower–extremity revascularization

Rationale and design of “Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)” study

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

A Cohort Study on the Safety and Efficacy of Warfarin and Rivaroxaban in Anticoagulant Therapy in Patients with Atrial Fibrillation Study.

Effectiveness of low-dose rivaroxaban in preventing recurrent major adverse cardiovascular events in coronary artery disease: a systematic review and meta-analysis of randomized controlled trials

Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome

Comparison of Rivaroxaban Mono-Therapy and Standard-Therapy Adjusted by CYP2C9 and VKORC1 Genotypes in Symptomatic Pulmonary Embolism.

A randomised trial on modulating endogenous fibrinolysis in patients with acute coronary syndrome VaLiDate-R

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness

Antithrombotic monotherapy for stable coronary artery disease and atrial fibrillation patients with and without prior coronary artery revascularization: Insights from the AFIRE trial